Associate Professor Jim Whittle, MBBS, PhD, FRACP / Katie Metrock, MD - Moving MEK Inhibitor Therapy FORWARD in NF1: A Neuro-Oncology FOrum on Real-World Application of Recent Data for Improving Patient Care
This episode discusses the application of MEK inhibitor therapy in NF1 and its implications for patient care.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/SKY865. CME/AAPA credit will be available until July 28, 2027. Moving MEK Inhibitor Therapy FORWARD in NF1: A Neuro-Oncology FO rum on R eal- W orld A pplication of R ecent D ata for Improving Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from SpringWorks, a healthcare company of Merck KGaA, Darmstadt, Germany. Disclosure information is available at the beginning of the video presentation.
People in this episode
Guests: Jim Whittle, Katie Metrock
Topics covered
MEK Inhibitor Therapy
Neuro-Oncology
Patient Care
Healthcare Education
NF1
Keywords
MEK Inhibitor
NF1
Neuro-Oncology
Patient Care
CME
Sponsors
SpringWorks
Mentioned in this episode
Organizations: PeerView Institute for Medical Education, Merck KGaA, Accreditation Council for Continuing Medical Education, Accreditation Council for Pharmacy Education, American Nurses Credentialing Center
More episodes of PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast